CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer

Dylan Daniel, Christopher Chiu, Enrico Giraudo, Masahiro Inoue, Lee A. Mizzen, N. Randall Chu, Douglas Hanahan

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

A major agenda for tumor immunology is the generation of specific immune responses leading to the destruction of incipient and frank neoplasia. In this report, we show that a novel HPV16 E7 fusion protein can produce objective therapeutic responses against incipient cervical cancer in genetically engineered mice that express in the cervix the HPV16 early region genes implicated as causative agents in human cervical cancer. Although nonresponsive toward the HPV16 E7 oncoprotein in the CD8+ T-cell compartment by virtue of MHC haplotype, the mice were capable of mounting an induced CD4 + T-cell response against E7, and in addition developed spontaneous anti-E7 antibodies. HPV16/CD4-/- mice showed increased tumor burden indicative of CD4-mediated immune surveillance. Seeking to enhance the CD4 response, we immunized mice bearing incipient cervical cancer with a recombinant protein fusing E7 with a mycobacterial heat shock protein. The incidences of cervical carcinoma and of high-grade dysplasia (CIN 3) were consequently reduced by comparison to control mice. Thus, an HPV16 E7 immunogen holds promise for noninvasive treatment and prevention of human cervical cancer.

Original languageEnglish
Pages (from-to)2018-2025
Number of pages8
JournalCancer Research
Volume65
Issue number5
DOIs
Publication statusPublished - Mar 1 2005

Fingerprint

Uterine Cervical Neoplasms
Immunotherapy
T-Lymphocytes
Antigens
Oncogene Proteins
Heat-Shock Proteins
Allergy and Immunology
Tumor Burden
Recombinant Proteins
Cervix Uteri
Haplotypes
Anti-Idiotypic Antibodies
Neoplasms
Carcinoma
Incidence
Therapeutics
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. / Daniel, Dylan; Chiu, Christopher; Giraudo, Enrico; Inoue, Masahiro; Mizzen, Lee A.; Chu, N. Randall; Hanahan, Douglas.

In: Cancer Research, Vol. 65, No. 5, 01.03.2005, p. 2018-2025.

Research output: Contribution to journalArticle

Daniel, D, Chiu, C, Giraudo, E, Inoue, M, Mizzen, LA, Chu, NR & Hanahan, D 2005, 'CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer', Cancer Research, vol. 65, no. 5, pp. 2018-2025. https://doi.org/10.1158/0008-5472.CAN-04-3444
Daniel, Dylan ; Chiu, Christopher ; Giraudo, Enrico ; Inoue, Masahiro ; Mizzen, Lee A. ; Chu, N. Randall ; Hanahan, Douglas. / CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. In: Cancer Research. 2005 ; Vol. 65, No. 5. pp. 2018-2025.
@article{217b3facfd18425cb2192a6c42320ef8,
title = "CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer",
abstract = "A major agenda for tumor immunology is the generation of specific immune responses leading to the destruction of incipient and frank neoplasia. In this report, we show that a novel HPV16 E7 fusion protein can produce objective therapeutic responses against incipient cervical cancer in genetically engineered mice that express in the cervix the HPV16 early region genes implicated as causative agents in human cervical cancer. Although nonresponsive toward the HPV16 E7 oncoprotein in the CD8+ T-cell compartment by virtue of MHC haplotype, the mice were capable of mounting an induced CD4 + T-cell response against E7, and in addition developed spontaneous anti-E7 antibodies. HPV16/CD4-/- mice showed increased tumor burden indicative of CD4-mediated immune surveillance. Seeking to enhance the CD4 response, we immunized mice bearing incipient cervical cancer with a recombinant protein fusing E7 with a mycobacterial heat shock protein. The incidences of cervical carcinoma and of high-grade dysplasia (CIN 3) were consequently reduced by comparison to control mice. Thus, an HPV16 E7 immunogen holds promise for noninvasive treatment and prevention of human cervical cancer.",
author = "Dylan Daniel and Christopher Chiu and Enrico Giraudo and Masahiro Inoue and Mizzen, {Lee A.} and Chu, {N. Randall} and Douglas Hanahan",
year = "2005",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-04-3444",
language = "English",
volume = "65",
pages = "2018--2025",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer

AU - Daniel, Dylan

AU - Chiu, Christopher

AU - Giraudo, Enrico

AU - Inoue, Masahiro

AU - Mizzen, Lee A.

AU - Chu, N. Randall

AU - Hanahan, Douglas

PY - 2005/3/1

Y1 - 2005/3/1

N2 - A major agenda for tumor immunology is the generation of specific immune responses leading to the destruction of incipient and frank neoplasia. In this report, we show that a novel HPV16 E7 fusion protein can produce objective therapeutic responses against incipient cervical cancer in genetically engineered mice that express in the cervix the HPV16 early region genes implicated as causative agents in human cervical cancer. Although nonresponsive toward the HPV16 E7 oncoprotein in the CD8+ T-cell compartment by virtue of MHC haplotype, the mice were capable of mounting an induced CD4 + T-cell response against E7, and in addition developed spontaneous anti-E7 antibodies. HPV16/CD4-/- mice showed increased tumor burden indicative of CD4-mediated immune surveillance. Seeking to enhance the CD4 response, we immunized mice bearing incipient cervical cancer with a recombinant protein fusing E7 with a mycobacterial heat shock protein. The incidences of cervical carcinoma and of high-grade dysplasia (CIN 3) were consequently reduced by comparison to control mice. Thus, an HPV16 E7 immunogen holds promise for noninvasive treatment and prevention of human cervical cancer.

AB - A major agenda for tumor immunology is the generation of specific immune responses leading to the destruction of incipient and frank neoplasia. In this report, we show that a novel HPV16 E7 fusion protein can produce objective therapeutic responses against incipient cervical cancer in genetically engineered mice that express in the cervix the HPV16 early region genes implicated as causative agents in human cervical cancer. Although nonresponsive toward the HPV16 E7 oncoprotein in the CD8+ T-cell compartment by virtue of MHC haplotype, the mice were capable of mounting an induced CD4 + T-cell response against E7, and in addition developed spontaneous anti-E7 antibodies. HPV16/CD4-/- mice showed increased tumor burden indicative of CD4-mediated immune surveillance. Seeking to enhance the CD4 response, we immunized mice bearing incipient cervical cancer with a recombinant protein fusing E7 with a mycobacterial heat shock protein. The incidences of cervical carcinoma and of high-grade dysplasia (CIN 3) were consequently reduced by comparison to control mice. Thus, an HPV16 E7 immunogen holds promise for noninvasive treatment and prevention of human cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=16444377935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16444377935&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-3444

DO - 10.1158/0008-5472.CAN-04-3444

M3 - Article

VL - 65

SP - 2018

EP - 2025

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 5

ER -